Trial reportCancer control : journal of the Moffitt Cancer Center
Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer.
Trial report in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Prediction of myelosuppression in cervical cancer after concurrent chemoradiotherapy by CT radiomics-based model.BMC medical imaging · 2026Article
- Development and validation of a machine learning-based predictive model for chemotherapy-induced myelosuppression in colorectal cancer patients.Frontiers in medicine · 2026Article
- Interpretable machine-learning prediction of severe myelosuppression in colorectal cancer patients receiving chemotherapy using XGBoost and SHAP: a retrospective study with a web-based calculator.Frontiers in oncology · 2026Article
- Real-World Clinical Outcomes of Trilaciclib for the Prevention of Myelosuppression in Patients with Esophageal Cancer Undergoing Chemotherapy.Current oncology (Toronto, Ont.) · 2025Article
- A nomogram for predicting the risk of chemoradiotherapy-associated thrombocytopenia in patients with esophageal cancer: a real-world cohort study.Therapeutic advances in medical oncology · 2025Article
- Radiomics model based on vertebral calcium-suppressed CT images for predicting chemotherapy-induced myelosuppression in nasopharyngeal carcinoma.Frontiers in oncology · 2025Article
- Development of a Predictive Model for the Risk of Myelosuppression in Patients With Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy.Clinical Medicine Insights. Oncology · 2025Article
- Development and validation of a prediction model for myelosuppression in lung cancer patients after platinum-based doublet chemotherapy: a multifactorial analysis approach.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe influential factors of chemotherapy-induced myelosuppression in esophageal cancer in central China are unclear. This study aimed to develop a model for prediction of incidence of myelosuppression during chemotherapy among patients with esophageal cancer.
methodsIn this retrospective study, a total of 1446 patients with esophageal cancer who underwent five different chemotherapy regimens between 2013 and 2020 at our institute were randomly assigned in a 7:3 ratio to training and validation data sets. Clinical and drug-related variables were used to develop the prediction model from the training data set by the machine learning method of random forest. Finally, this model were tested in the validation data set.
resultsThe prediction model were established with 16 indispensable variables selected from 46 variables. The model obtained an area under the receiver-operating characteristic curve of .883 and accompanied by prediction accuracy of 80.0%, sensitivity of 77.8% and specificity of 81.8%.
conclusionThis new prediction model showed excellent predictive ability of incidence of myelosuppression in turn providing preventative measures for patients with esophageal cancer during chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.